# A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease

> **NCT06388083** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Belite Bio, Inc** · enrollment: 60 (estimated)

## Conditions studied

- STGD1
- Stargardt Disease 1

## Interventions

- **DRUG:** Tinlarebant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06388083
- **Lead sponsor:** Belite Bio, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-31
- **Primary completion:** 2028-02
- **Final completion:** 2028-02
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06388083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06388083, "A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06388083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*